Likelihood of Approval and Phase Transition Success Rate Model – Nirmatrelvir + Ritonavir in Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Nirmatrelvir + Ritonavir in Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Nirmatrelvir + Ritonavir in Post-Acute Sequelae of COVID 2019 (PASC or Long COVID) Drug Details:
Nirmatrelvir and ritonavir (Paxlovid / Skyvira) are oral antiviral agents in which nirmatrelvir tablets co-packaged with ritonavir tablets. It is formulated as tablets, coated tablets, film coated tablets for oral route of administration. It is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is indicated for the treatment of coronavirus disease (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19. Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID-19) for adults and children aged 12 years or older and weighing 40 kg or more. Paxlovid is indicated for the treatment of adults with mild to moderate novel coronavirus pneumonia (COVID-19) with high risk factors for progression to severe disease. Paxlovid is indicated for the treatment of coronavirus disease 2019 (COVID- 19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to COVID-19 and are at increased risk of progression to hospitalisation or death.Paxlovid is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and long covid. The drug candidate is a combination of nirmatrelvir [PF-07321332] tablets and ritonavir tablets. Low dose of ritonavir is given to boost the pharmacokinetics of the PF-07321332. It is administered through oral route and acts by targeting SARS-CoV-2 3C-like protease and HIV 1 Retropepsin.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Nirmatrelvir + Ritonavir LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports